China’s Genor Biopharma Co. Ltd. agreed to out-license GB-261, its bispecific antibody candidate primarily targeting B-cell lymphomas, to TRC 2004 Inc., a U.S.-based newco co-founded by Third Rock Ventures LLC and Two River Group Holdings LLC.
Yellowstone Biosciences Ltd. has launched with a focus on soluble bispecific T-cell receptor (TCR)-based therapies for human leukocyte antigen (HLA) class II (HLA-II) targets in oncology.
Arbele Ltd. founder and CEO John Luk identified and patented cadherin-17 as a therapeutic cancer target, and the company was founded to develop immunotherapies for gastrointestinal cancers, which are prevalent in Asia Pacific.
At the ongoing AACR meeting, Amgen Inc. provided details on the discovery and preclinical characterization of AMG-305, a novel dual-targeting bispecific T-cell engager (BiTE) molecule, being developed as a potential new anticancer agent. While BiTE molecules offer a targeted immune therapy approach to treat cancer, on-target toxicity from normal tissue target expression has been a key issue in the development of T-cell engager molecules in solid tumors.
Seagen Inc. and Lava Therapeutics NV have entered into an exclusive license agreement under which Seagen will work to develop, manufacture and commercialize LAVA-1223, a bispecific T-cell engager designed to target and activate Vγ9Vδ2 T cells in the presence of epidermal growth factor receptor (EGFR)-expressing solid tumors.
DUBLIN – Merus NV is banking $40 million up front, plus an equity investment of $20 million, under a research collaboration and license agreement with Eli Lilly and Co.’s Loxo Oncology arm to develop up to three CD3-directed bispecific T-cell engager antibodies. Each program also has up to $540 million attached in development and commercialization milestones, taking the total potential value of the deal to $1.68 billion. Merus would also receive tiered royalties on any product sales, ranging, in percentage terms, from mid-single-digits to low-double-digits.
